Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma
Volume
15
Pagination
172 - 183
DOI
10.1158/1535-7163.MCT-15-0170
Journal
MOLECULAR CANCER THERAPEUTICS
Issue
ISSN
1535-7163